Alere Triage Meter Pro
DeviceTroponin and BNP measured on point of care meter.
Other names: Point of Care Meter
NCT Number: NCT01634425
The purpose of this study is to determine if early diagnosis and risk stratification acquired through pre-hospital clinical assessment, 12-lead electrocardiogram and point of care biomarkers will facilitate enhanced triage and treatment in patients with presumed non-ST elevation acute coronary syndromes (NSTEMI).
Looking for future studies?
Notify Me31 year and older
All sexes
Interventional
Phase 4
Grey Nuns Community Hospital, Edmonton, Alberta, Canada
Utilizing the platform of pre-hospital STEMI research and clinical experience developed over the past decade; we now intend to investigate how best to achieve timely diagnosis and risk stratification of patients that present to pre-hospital emergency medical services with symptoms suspicious for acute NSTEMI through utilization of systematic clinical assessment, pre-hospital 12 lead electrocardiogram and point of care measurement of biomarkers. Additionally, where deemed appropriate these patients will be enrolled in a clinical Chest Pain Protocol utilizing the pre-hospital biomarkers. We hypothesize that establishing a pre-hospital diagnosis in this condition may facilitate efficient triage and -as appropriate- in-hospital disposition. Additionally, the enhanced pre-hospital assessment of this population will facilitate appropriate timely disposition of those patients not found to have acute cardiovascular disease. These processes will facilitate decanting the frequently overcrowded and under resources Emergency Departments.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Troponin and BNP measured on point of care meter.
Other names: Point of Care Meter
Time frame: From date of first medical contact until first appropriate therapy given, assessed up to 30 months
An Adjudication Committee will examine the records to determine final diagnosis.
Final patient disposition is defined as the time when a plan for patient discharge from the ED or admission to hospital is both established and documented.
Time frame: Assessed up to 30 months.
From time of first medical contact to First appropriate therapy for NSTEMI is defined as: receiving oral antiplatelet agent (excluding ASA - which is routinely administered prior to diagnosis) or intravenous/subcutaneous antithrombotic agents (low molecular weight heparin or IV heparin or glycoprotein IIb/IIIa receptor inhibitors).
Time frame: Assessed up to 30 months
Time frame: Assessed up to 30 months
Time frame: Assessed up to 30 months
Time frame: Assessed up to 30 months
Time frame: Assessed up to 30 months
Time frame: Assessed up to 30 months
University of Alberta
Other
Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT) Novel Proximal Pathways for Non ST Elevation Myocardial Infarction
Acronym: PROACT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07204847
Cardiovascular Diseases, Heart Diseases
Montpellier, France
View Trial DetailsNCT05175261
Cardiovascular Diseases, Heart Diseases
Burlington, Vermont, United States
View Trial DetailsNCT06404515
ASCVD, Acute Coronary Syndrome
New York, United States
View Trial DetailsNCT01197742
Cardiovascular Diseases, Diabetes
München, Germany
View Trial Details